[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GR3032101T3 - Vehicles for oral administration of a specific pharmaceutically active acid labile substance. - Google Patents

Vehicles for oral administration of a specific pharmaceutically active acid labile substance.

Info

Publication number
GR3032101T3
GR3032101T3 GR990403191T GR990403191T GR3032101T3 GR 3032101 T3 GR3032101 T3 GR 3032101T3 GR 990403191 T GR990403191 T GR 990403191T GR 990403191 T GR990403191 T GR 990403191T GR 3032101 T3 GR3032101 T3 GR 3032101T3
Authority
GR
Greece
Prior art keywords
vehicles
oral administration
pharmaceutically active
acid labile
active acid
Prior art date
Application number
GR990403191T
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26290693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3032101(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GR3032101T3 publication Critical patent/GR3032101T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GR990403191T 1986-04-30 1999-12-10 Vehicles for oral administration of a specific pharmaceutically active acid labile substance. GR3032101T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB08610572A GB2189698A (en) 1986-04-30 1986-04-30 Coated omeprazole tablets
SG154294A SG154294G (en) 1986-04-30 1994-10-21 New pharmaceutical preparation for oral use

Publications (1)

Publication Number Publication Date
GR3032101T3 true GR3032101T3 (en) 2000-03-31

Family

ID=26290693

Family Applications (4)

Application Number Title Priority Date Filing Date
GR89300058T GR890300058T1 (en) 1986-04-30 1989-06-22 New pharmaceutical preparation for oral use
GR930400621T GR3007434T3 (el) 1986-04-30 1993-03-23
GR960402099T GR3020734T3 (en) 1986-04-30 1996-08-07 Use of specific core material and layers to obtain pharmaceutical formulations stable to discolouration of omeprazole
GR990403191T GR3032101T3 (en) 1986-04-30 1999-12-10 Vehicles for oral administration of a specific pharmaceutically active acid labile substance.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
GR89300058T GR890300058T1 (en) 1986-04-30 1989-06-22 New pharmaceutical preparation for oral use
GR930400621T GR3007434T3 (el) 1986-04-30 1993-03-23
GR960402099T GR3020734T3 (en) 1986-04-30 1996-08-07 Use of specific core material and layers to obtain pharmaceutical formulations stable to discolouration of omeprazole

Country Status (35)

Country Link
US (1) US4786505A (el)
EP (3) EP0567201B1 (el)
JP (2) JPS62258320A (el)
KR (1) KR910004579B1 (el)
CN (1) CN1020852C (el)
AR (1) AR240250A1 (el)
AT (3) ATE140387T1 (el)
CA (1) CA1292693C (el)
CY (1) CY1810A (el)
DD (1) DD273197A5 (el)
DE (3) DE247983T1 (el)
DK (1) DK169988B1 (el)
DZ (1) DZ1077A1 (el)
ES (3) ES2135443T3 (el)
FI (1) FI90393C (el)
GB (1) GB2189698A (el)
GR (4) GR890300058T1 (el)
HK (2) HK135294A (el)
HR (1) HRP920854B1 (el)
HU (1) HU196708B (el)
IE (1) IE61416B1 (el)
IL (1) IL82911A (el)
IS (1) IS1917B (el)
LT (1) LT3699B (el)
LV (2) LV10357B (el)
NO (1) NO174239C (el)
NZ (1) NZ220096A (el)
PH (1) PH25701A (el)
PL (1) PL151631B1 (el)
PT (1) PT84785B (el)
RU (2) RU1820837C (el)
SG (1) SG154294G (el)
SI (1) SI8710681A8 (el)
YU (1) YU46192B (el)
ZA (1) ZA872378B (el)

Families Citing this family (364)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749864B2 (en) * 1986-02-13 2004-06-15 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
JPH0737383B2 (ja) * 1988-07-11 1995-04-26 エーザイ株式会社 胃酸分泌抑制剤含有固型製剤
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
EP0425699B1 (en) * 1989-05-11 1994-08-17 Chugai Seiyaku Kabushiki Kaisha Oral preparation which can be released at suitable region in intestine
US5540945A (en) * 1989-05-11 1996-07-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
CA2052698A1 (en) * 1990-10-11 1992-04-12 Roger G. Berlin Treatment of peptic ulcer
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
EP0519144B1 (en) * 1991-06-21 1997-08-13 Ilsan Ilac Ve Hammaddeleri Sanayi A.S. New galenic process for omeprazole containing pellets
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
HU9202318D0 (en) * 1991-07-22 1992-10-28 Bristol Myers Squibb Co Method for preparing medical preparatives containing didesoxi-purine nucleoside
DE69231313T2 (de) * 1991-11-22 2001-03-15 Procter & Gamble Pharmaceuticals, Inc. Risedronat enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
AU4513393A (en) * 1992-07-17 1994-02-14 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
GB9223702D0 (en) 1992-11-12 1992-12-23 Lucas Ind Plc Improvements in hydraulic braking systems for vehicles
ATE195252T1 (de) * 1993-04-23 2000-08-15 Novartis Erfind Verwalt Gmbh Wirkstoffabgabevorrichtung mit gesteuerter freigabe
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
TW397686B (en) * 1993-08-11 2000-07-11 Takeda Chemical Industries Ltd Antacid compositions and pharmaceutical compositions
TW280770B (el) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
WO1995018612A1 (en) * 1994-01-05 1995-07-13 Aktiebolaget Astra A method for treatment of psoriasis, by omeprazole or related compounds
WO1995022962A1 (en) * 1994-02-23 1995-08-31 Bm Research A/S Controlled release composition
BR9508261A (pt) * 1994-07-08 1997-12-23 Astra Ab Formulação oral entericamente revestida uso da mesma processo para preparer a formulação inibir a secreção de ácido gástrico em mamíferos e no ser humano e tratar doenças relacionadas ao ácido gástrico em maníferos e no ser humano e pacote de empola de pressão transversal
US5817338A (en) * 1994-07-08 1998-10-06 Astra Aktiebolag Multiple unit tableted dosage form of omeprazole
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
HU217093B (hu) * 1994-11-21 1999-11-29 Shell Internationale Research Maatschappij B.V. Bitumenkompozíciók, valamint azok előállítása és alkalmazása
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US7008668B2 (en) * 1995-05-09 2006-03-07 Phoqus Pharmaceuticals Limited Powder coating composition for electrostatic coating of pharmaceutical substrates
GB2316342B (en) * 1995-05-09 2000-01-12 Colorcon Ltd Electrostatic coating
JP4137998B2 (ja) 1995-05-09 2008-08-20 フオカス リミテッド 医薬基材の静電塗装用粉末塗装組成物
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
ES2220989T3 (es) * 1995-09-21 2004-12-16 Pharma Pass Ii Llc Nueva composicion que contiene benzimidazol labil al acido y procedimiento para su preparacion.
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE9600071D0 (sv) † 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
ZA979937B (en) * 1996-11-06 1999-05-18 Sharmatek Inc Delayed delivery system for acid-sensitive drugs
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
GB9623634D0 (en) 1996-11-13 1997-01-08 Bpsi Holdings Inc Method and apparatus for the coating of substrates for pharmaceutical use
AU5446798A (en) * 1996-11-27 1998-06-22 Procter & Gamble Company, The Compositions and methods for the treatment of gastrointestinal disorders
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
TW550090B (en) * 1997-05-09 2003-09-01 Sage Pharmaceuticals Inc Stable oral pharmaceutical dosage forms for acid-unstable drug
GB9710800D0 (en) * 1997-05-23 1997-07-23 Cipla Limited Pharmaceutical composition and method of preparing it
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
SE9702533D0 (sv) 1997-07-01 1997-07-01 Astra Ab New oral formulation
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6296876B1 (en) 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
DE19752843C2 (de) * 1997-11-28 2003-01-09 Byk Gulden Lomberg Chem Fab Arzneimittelzubereitung in Tabletten- oder Pelletform für Pantoprazol und Omeprazol
PT1037607E (pt) * 1997-12-08 2004-07-30 Altana Pharma Ag Nova forma de supositorio compreendendo um composto activo instavel em acido
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774288B1 (fr) 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
JP4127740B2 (ja) * 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化したベンズイミダゾール系化合物含有組成物
CN1141097C (zh) * 1998-04-20 2004-03-10 卫材株式会社 含有稳定化的苯并咪唑类化合物的组合物
EP1121103B1 (en) 1998-05-18 2006-12-20 Takeda Pharmaceutical Company Limited Orally disintegrable tablets comprising a benzimidazole
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
WO2000009092A1 (en) * 1998-08-12 2000-02-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
US7094426B2 (en) * 1998-08-27 2006-08-22 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
KR100314351B1 (ko) * 1998-10-01 2002-03-21 민경윤 벤즈이미다졸유도체의장용성제제및그제조방법
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
DK1131316T3 (da) * 1998-11-18 2004-09-27 Astrazeneca Ab Forbedret kemisk fremgangsmåde og farmaceutisk præparat
RU2144823C1 (ru) * 1998-11-20 2000-01-27 Научно-исследовательский институт фармакологии Томского научного центра РАМН Лекарственное средство, обладающее слабительным действием
TWI242000B (en) 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6197329B1 (en) 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
RU2259828C2 (ru) 1999-10-20 2005-09-10 Эйсай Ко., Лтд. Способы стабилизации соединений на основе бензимидазола
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
DE19959419A1 (de) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
GB0002305D0 (en) 2000-02-01 2000-03-22 Phoqus Limited Power material for electrostatic application
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US6306435B1 (en) * 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
SI20720A (sl) * 2000-11-20 2002-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nov farmacevtski pripravek v obliki celuloznih kapsul uporaben za derivate benzimidazola
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
CA2440641A1 (en) * 2001-03-13 2002-09-19 Anand R. Baichwal Chronotherapeutic dosage forms containing glucocorticosteroid
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
CN1529587B (zh) * 2001-05-30 2010-05-12 欧洲凯尔特公司 含有粪便软化剂泊洛沙姆和包有肠溶衣的比沙可定颗粒的药物组合物
CA2449098C (en) * 2001-06-01 2010-01-05 John R. Plachetka Pharmaceutical compositions for the coordinated delivery of nsaids
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20030235628A1 (en) * 2001-09-19 2003-12-25 Rajneesh Taneja Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
BR0213593A (pt) 2001-09-28 2004-08-31 Mcneil Ppc Inc Formas de dosagens de liberação modificada
PT1459737E (pt) * 2001-10-17 2012-11-26 Takeda Pharmaceutical Grânulos contendo um composto químico instável em meio ácido em concentração elevada
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
ES2198195B1 (es) * 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
ATE363480T1 (de) 2002-03-05 2007-06-15 Astrazeneca Ab Alkylammoniumsalze von omeprazol und esomeprazol
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) * 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
GB2392839A (en) * 2002-03-08 2004-03-17 Bakulesh Mafatlal Khamar Use of Mycobacterium w in the treatment of tuberculosis
US20030180358A1 (en) * 2002-03-25 2003-09-25 Stumberger Walter William System and method for affecting the pH state of the contents of the distal bowel in mammals
CA2477841A1 (en) * 2002-03-28 2003-10-09 Astrazeneca Ab Method of use
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040005362A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of acid labile drugs
RU2332237C2 (ru) * 2002-08-02 2008-08-27 Рациофарм Гмбх Фармацевтический препарат, содержащий производное бензимидазола, смешанное с микрокристаллической целлюлозой, и способ его изготовления
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US20050191353A1 (en) * 2002-08-16 2005-09-01 Amit Krishna Antarkar Process for manufacture of stable oral multiple unit pharmaceutical composition containing benzimidazoles
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
AU2003273000A1 (en) * 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
AU2003297736A1 (en) * 2002-12-23 2004-07-29 Celltech Americas, Inc. Acid labile drug compositions
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
CA2518780C (en) 2003-03-12 2014-05-13 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
TW200503783A (en) * 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
CA2523218A1 (en) * 2003-04-22 2004-11-04 Dr. Reddy's Laboratories Limited Oral pharmaceutical formulations of acid-labile active ingredients and process for making same
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
GB2420297B (en) * 2003-06-18 2006-11-15 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
NZ544608A (en) * 2003-07-17 2008-07-31 Reddys Lab Ltd Dr Pharmaceutical compositions having a swellable coating comprising prolamin
US20050147663A1 (en) * 2003-07-17 2005-07-07 Mohan Mailatur S. Method of treatment for improved bioavailability
RU2375048C2 (ru) * 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
US20050232992A1 (en) * 2003-09-03 2005-10-20 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
WO2005027843A2 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
CA2539051C (en) * 2003-09-19 2014-08-12 Penwest Pharmaceuticals Co. Delayed release dosage forms
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
EP1667681A4 (en) * 2003-10-03 2009-09-30 Astron Res Pvt Ltd NEW TRANSMUCOSAL ADMINISTRATION SYSTEM
DK1692516T3 (da) * 2003-10-24 2011-02-28 Immunaid Pty Ltd Terapifremgangsmåde
CA2543172A1 (en) * 2003-10-31 2005-05-19 Dexcel Ltd. Stable lansoprazole formulation
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
GB0330171D0 (en) * 2003-12-30 2004-02-04 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
US20070141150A1 (en) * 2003-12-30 2007-06-21 Raghupathi Kandarapu Pharmaceutical composition
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
MXPA06009991A (es) * 2004-03-03 2007-04-10 Teva Pharma Una composicion farmaceutica estable que comprende un farmaco labil acido.
CA2557634A1 (en) * 2004-03-04 2005-09-15 Takeda Pharmaceutical Company Limited Stable capsule preparation
CA2560613C (en) * 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
GB0407312D0 (en) * 2004-03-31 2004-05-05 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1750767A4 (en) * 2004-05-25 2010-09-22 Santarus Inc PHARMACEUTICAL FORMULATIONS USEFUL IN INHIBITING ACID SECRETION AND METHODS OF MAKING AND USING SAME
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2469427A1 (en) * 2004-06-01 2005-12-01 Pharmascience Inc. Dry mixed dosage form containing benzimidazole derivatives
US20060051421A1 (en) * 2004-06-15 2006-03-09 Nava Shterman Stable pharmaceutical formulations of benzimidazole compounds
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP1796730B1 (en) * 2004-09-20 2010-07-21 LTB4 Sweden AB Stabilized leukotriene b4 (ltb4) agent pharmaceutical
EP1830823A2 (en) 2004-12-23 2007-09-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
WO2006085335A2 (en) * 2005-01-03 2006-08-17 Lupin Limited Pharmaceutical composition of acid labile substances
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
US20080279951A1 (en) * 2005-02-02 2008-11-13 Rajesh Gandhi Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2006111853A2 (en) * 2005-04-18 2006-10-26 Aurobindo Pharma Limited Stable solid dosage forms of acid labile drug
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
ES2635308T3 (es) 2005-07-29 2017-10-03 Abbott Laboratories Gmbh Pancreatina con contenido viral reducido
DE602006012346D1 (de) * 2005-08-15 2010-04-01 Solvay Pharm Gmbh Pharmazeutische zusammensetzungen mit kontrollierter freisetzung für säurelabile arzneimittel
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
CA2619475C (en) * 2005-08-15 2015-09-29 Solvay Pharmaceuticals Gmbh Controlled release pharmaceutical compositions for acid labile drugs
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
WO2007041790A1 (en) * 2005-10-14 2007-04-19 Jon Pty Limited Salts of proton pump inhibitors and process for preparing same
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
EP1785135A1 (en) * 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. New stabilized galenic formulations comprising lansoprazole and their preparation
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
WO2007067128A1 (en) 2005-12-05 2007-06-14 Astrazeneca Ab New process for the preparation of esomeprazole non-salt form
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1967184A4 (en) * 2005-12-28 2011-02-16 Takeda Pharmaceutical SOLID PREPARATION WITH CONTROLLED RELEASE
JP5053865B2 (ja) 2005-12-28 2012-10-24 武田薬品工業株式会社 口腔内崩壊性固形製剤の製造法
WO2007078874A2 (en) * 2005-12-30 2007-07-12 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
JP2009523784A (ja) 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド 酸不安定化合物の安定な医薬製剤およびその製造方法
BRPI0707325A2 (pt) 2006-01-27 2011-05-03 Eurand Inc formulação de dosagem de liberação multiparticulada e método para preparação da mesma
US20070190145A1 (en) * 2006-01-27 2007-08-16 Eurand, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
US7776831B2 (en) 2006-02-01 2010-08-17 Weg Stuart L Use of antifungal compositions to treat upper gastrointestinal conditions
EP2007360B1 (en) 2006-04-03 2014-11-26 Isa Odidi Controlled release delivery device comprising an organosol coat
TR201816133T4 (tr) 2006-04-04 2018-11-21 Kg Acquisition Llc Bi̇r anti̇platelet ajan ve bi̇r asi̇t i̇nhi̇bi̇törü i̇çeren oral dozaj formlari.
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico
EP2026768B1 (en) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
AR056062A1 (es) * 2006-06-05 2007-09-19 Bago Sa Labor Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion
JP5474541B2 (ja) 2006-07-25 2014-04-16 ベクタ・リミテッド 小さいジカルボン酸の誘導体と組み合わせてｐｐｉを用いる胃酸分泌を阻害する組成物および方法
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
PL2124556T3 (pl) 2006-10-09 2015-02-27 Charleston Laboratories Inc Kompozycje farmaceutyczne
WO2008047320A2 (en) * 2006-10-17 2008-04-24 Ranbaxy Laboratories Limited Multiple unit tablet compositions of benzimidazole compounds
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US8352042B2 (en) * 2006-11-28 2013-01-08 The Alfred E. Mann Foundation For Scientific Research Remote controls and ambulatory medical systems including the same
US20110174855A1 (en) * 2006-11-29 2011-07-21 Yakima Products, Inc. Vehicle top carriers
PL2124884T3 (pl) 2006-12-22 2020-01-31 Ironwood Pharmaceuticals, Inc. Metody i kompozycje do leczenia zaburzeń przełyku
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
CN103933555B (zh) * 2007-02-20 2018-06-01 阿普塔利斯制药有限公司 稳定的消化酶组合物
US20090117180A1 (en) * 2007-02-20 2009-05-07 Giovanni Ortenzi Stable digestive enzyme compositions
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
PL2152250T3 (pl) * 2007-05-07 2020-06-15 Evonik Röhm Gmbh Stałe postaci dawkowania zawierające otoczkę dojelitową o przyspieszonym uwalnianiu leku
WO2009012393A1 (en) * 2007-07-18 2009-01-22 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor and protein component
WO2009049160A1 (en) 2007-10-12 2009-04-16 Takeda Pharmaceuticals North America Methods of treating gastrointestinal disorders independent of the intake of food
ITFI20070253A1 (it) * 2007-11-09 2009-05-10 Valpharma Internat S P A Formulazioni farmaceutiche per la somministrazione di ipp.
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
CA3066426A1 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
AU2009215514B9 (en) 2008-02-20 2014-01-30 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
AU2009267145A1 (en) * 2008-06-30 2010-01-07 Merck Sharp & Dohme Corp. Solid dosage formulations of telcagepant potassium
NZ588311A (en) * 2008-07-24 2012-08-31 Handa Pharmaceuticals Llc Stabilized atypical antipsychotic formulation to treat psychiatric conditions
JP2011530569A (ja) * 2008-08-11 2011-12-22 メファ・ゲーエムベーハー 特定の分離層を含むオメプラゾールの経口医薬製剤
DE102008045339A1 (de) 2008-09-01 2010-03-04 Stada Arzneimittel Ag Pharmazeutisches Pellet
CN102209529A (zh) * 2008-09-09 2011-10-05 阿斯利康(瑞典)有限公司 将药物组合物递送至有需要的患者的方法
SG173832A1 (en) 2009-02-24 2011-09-29 Ritter Pharmaceuticals Inc Prebiotic formulations and methods of use
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
PL2435825T3 (pl) 2009-05-27 2015-12-31 Biotempus Ltd Sposoby leczenia chorób
WO2010151216A1 (en) 2009-06-25 2010-12-29 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
JP2011037787A (ja) * 2009-08-13 2011-02-24 Kyorin Pharmaceutical Co Ltd 塩基性薬物のｐＨに依存しない安定放出組成物
US20120141584A1 (en) * 2009-08-26 2012-06-07 Aptapharma, Inc. Multilayer Minitablets
EP2319504A1 (en) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
WO2011137249A1 (en) 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
WO2011138797A2 (en) 2010-05-04 2011-11-10 Cadila Healthcare Limited Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
BR112013007640A2 (pt) 2010-10-01 2017-09-26 Aptalis Pharma Ltd "composição, forma de dosagem, pacote, processo para a preparação da composição, processo para a preparação da forma de dosagem, método para tratamento ou prevenção de um distúrbio ou afecção associada a uma defeciência de enzima digestiva, método de terapia de substituição de enzima pacnreática e método para aperfeiçoar resultados nutricionais e de crescimento"
DE102010052847A1 (de) 2010-11-29 2012-05-31 Temmler Werke Gmbh Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US8568776B2 (en) 2011-02-11 2013-10-29 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
RU2602183C2 (ru) 2011-08-08 2016-11-10 Апталис Фарма Лтд. Способ проведения теста на растворение твердых композиций, содержащих пищеварительные ферменты
GB201117480D0 (en) 2011-10-10 2011-11-23 Palikaras George Filter
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
EA028049B1 (ru) 2011-12-28 2017-10-31 Поузен Инк. Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
KR102160388B1 (ko) 2012-03-19 2020-09-28 버크 인스티튜트 포 리서치 온 에이징 App 특이적 bace 억제제(asbi) 및 이의 용도
JP2015524477A (ja) 2012-08-07 2015-08-24 バック・インスティテュート・フォー・リサーチ・オン・エイジング 神経機能を改善するための多成分製剤
CN102940611B (zh) * 2012-11-26 2017-02-22 康普药业股份有限公司 一种含有埃索美拉唑镁的肠溶片剂
CN102961356A (zh) * 2012-12-11 2013-03-13 山西云鹏制药有限公司 一种含奥美拉唑的蓝色肠溶片剂的制备方法
WO2014113377A1 (en) 2013-01-15 2014-07-24 Ironwood Pharmaceuticals, Inc. Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant
CN104995176B (zh) 2013-02-12 2019-02-22 巴克老龄化研究所 调节bace所介导的app加工的乙内酰脲
JP5934835B2 (ja) * 2013-03-08 2016-06-15 富士フイルム株式会社 腸溶性細粒及び医薬組成物
KR101616679B1 (ko) * 2013-04-23 2016-04-28 제트엑스 파마 엘엘씨 장용 코팅된 다중 미립자 제어 방출 페퍼민트 오일 조성물 및 관련 방법
EP3639846B1 (en) 2013-08-09 2022-09-28 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
US20170027876A1 (en) * 2013-12-20 2017-02-02 9286-3620 Quebec Inc. Protein-based enteric coating for oral dosage forms
CN104490840B (zh) * 2013-12-30 2018-09-28 成都迪康药业股份有限公司 泮托拉唑钠肠溶制剂及其制备方法
CN104337789B (zh) * 2013-12-30 2016-05-11 成都迪康药业有限公司 雷贝拉唑钠肠溶制剂及其制备方法
CN104337788B (zh) * 2013-12-30 2016-05-11 成都迪康药业有限公司 埃索美拉唑钠肠溶制剂及其制备方法
KR101658275B1 (ko) 2014-01-20 2016-09-20 대원제약주식회사 에스오메프라졸 함유 소형 의약정제
EP3125905A4 (en) 2014-04-04 2017-11-08 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
CA2947998A1 (en) 2014-06-19 2015-12-23 Aptalis Pharma Ltd. Methods for removing viral contaminants from pancreatic extracts
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US20180015118A1 (en) 2015-02-03 2018-01-18 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
EP3288556A4 (en) * 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
BE1024339B1 (fr) * 2016-07-01 2018-01-29 Be Pharbel Mfg Sa Microparticules multicouches libérant un composé pharmaceutiquement actif dans une forme pharmaceutique liquide
FI3324948T3 (fi) 2015-07-17 2023-05-05 Be Pharbel Mfg Monikerroksisia farmaseuttisesti aktiivista yhdistettä vapauttavia mikropartikkeleita nestemäisessä annosmuodossa
EP3117824A1 (en) * 2015-07-17 2017-01-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
US20190240187A1 (en) * 2015-11-27 2019-08-08 Symrise Ag Oral preparations with omeprazole or pantoprazole
KR102408525B1 (ko) 2016-01-08 2022-06-13 더 리전트 오브 더 유니버시티 오브 캘리포니아 화물 전달용 지질 2중층 코팅물을 가진 메조다공성 실리카 나노입자
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
WO2017152130A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
JP7027341B2 (ja) 2016-05-12 2022-03-01 バック・インスティテュート・フォー・リサーチ・オン・エイジング Ａｐｐの正常なプロセシングを促進する化合物
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3292862A1 (en) 2016-09-07 2018-03-14 Sandoz Ag Omeprazole formulations
EP3600320A4 (en) * 2017-03-31 2020-12-16 Acura Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR THE SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL SUBSTANCES
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)
WO2018236955A1 (en) 2017-06-23 2018-12-27 The Regents Of The University Of California IMPROVING GABA CAPACITY TO MODULATE IMMUNE RESPONSES
KR102227486B1 (ko) * 2017-06-30 2021-03-12 롯데정밀화학 주식회사 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법
CA3088630A1 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
EP3735250A4 (en) 2018-01-01 2022-04-13 The Regents Of The University Of California INDUSTRIAL-SCALE SYNTHESIS OF SILICASOMES-TYPE NANOSUPPORTS
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
KR102080023B1 (ko) * 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
RU2694527C1 (ru) 2018-02-06 2019-07-16 Шмуэль Борис Левит Комбинация для регенеративной терапии больных сахарным диабетом 1 типа
BR112021002796A2 (pt) 2018-08-23 2021-05-04 Chong Kun Dang Pharmaceutical Corp. composição farmacêutica e método para preparar uma composição farmacêutica
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
WO2020051379A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN118184678A (zh) 2019-01-22 2024-06-14 艾奥维安制药公司 Mtorc调节剂及其用途
CA3143713A1 (en) 2019-06-19 2020-12-24 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
TW202126301A (zh) * 2019-10-04 2021-07-16 愛爾蘭商席歐拉斯製藥有限公司 小兒懸浮調配物
KR20220113941A (ko) * 2019-12-11 2022-08-17 에보닉 오퍼레이션스 게엠베하 질환을 치료 또는 예방하는데 사용하기 위한 투여 형태
SI4072533T1 (sl) 2019-12-11 2025-04-30 Evonik Operations Gmbh Dozirna oblika, ki vsebuje alkalno sredstvo in plast enterične obloge
HUE066609T2 (hu) 2019-12-11 2024-08-28 Evonik Operations Gmbh Adagolási forma betegség kezelésében vagy megelõzésében történõ alkalmazásra
CN114569580B (zh) * 2020-12-02 2024-03-01 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
CN114569579B (zh) 2020-12-02 2023-10-31 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
ES2924573B2 (es) * 2021-03-18 2024-04-24 Aora Health S L Sistema de administracion en multiples sitios para administracion diferencial en el tracto gastrointestinal
CN112919975B (zh) * 2021-04-01 2022-02-11 山东爱福地生物股份有限公司 一种智能调控土壤酸碱度的有机肥的生产工艺
AU2022391767A1 (en) 2021-11-22 2024-07-04 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
KR20250006830A (ko) 2022-03-04 2025-01-13 레바제닉스 인코포레이티드 광역 스펙트럼 아미노글리코시드 및 이의 용도
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification
WO2025064621A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating colorectal cancer
WO2025064645A1 (en) 2023-09-19 2025-03-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for treating inflammatory bowel disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2540979A (en) * 1948-04-24 1951-02-06 Smith Kline French Lab Enteric coating
GB760403A (en) * 1952-10-16 1956-10-31 Abbott Lab Improvements in or relating to enteric coatings
DE1204363B (de) * 1963-09-10 1965-11-04 Hoffmann La Roche Verfahren zur Herstellung einer oralen Arzneizubereitung, die ihren Wirkstoff erst im Ileum abgibt
DE1617615A1 (de) * 1966-05-03 1971-03-25 Merck Patent Gmbh Verfahren zur Herstellung von oral vertraeglichen festen Arzneimittelzubereitungen mit Resorptionsverzoegerung
GB1190387A (en) * 1966-05-24 1970-05-06 Green Cross Corp Enteric Coated Medicaments
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
ZA743391B (en) * 1974-05-28 1975-08-27 A Warren Therapeutic products
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4382091A (en) * 1981-04-30 1983-05-03 Syntex (U.S.A.) Inc. Stabilization of 1-substituted imidazole derivatives in talc
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
JPS58135806A (ja) * 1982-02-08 1983-08-12 Nippon Kayaku Co Ltd 多層コ−チング製剤
JPS5920219A (ja) * 1982-07-26 1984-02-01 Shin Etsu Chem Co Ltd 腸溶性コ−テイング製剤の製造方法
DE3233764C2 (de) * 1982-09-11 1987-05-07 R.P. Scherer GmbH, 6930 Eberbach Verfahren zur Herstellung oraler Dosierungseinheiten
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPS6019715A (ja) * 1983-07-12 1985-01-31 Nisshin Flour Milling Co Ltd 安定なイソカルボスチリル製剤
AU571312B2 (en) * 1984-02-10 1988-04-14 Nycomed Danmark A/S Diffusion coated multiple-units dosage form
SE8404065D0 (sv) * 1984-08-10 1984-08-10 Haessle Ab Novel biologically active compounds
US4685919A (en) * 1985-03-14 1987-08-11 Ngk Spark Plug Co., Ltd. Artificial joint
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
JPS62277322A (ja) * 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物

Also Published As

Publication number Publication date
DE3751860T2 (de) 1996-11-21
ATE84215T1 (de) 1993-01-15
RU1820837C (ru) 1993-06-07
EP0567201A2 (en) 1993-10-27
IE61416B1 (en) 1994-11-02
HU196708B (en) 1989-01-30
YU68187A (en) 1988-12-31
DE3783394T2 (de) 1993-05-06
DE3783394D1 (de) 1993-02-18
FI90393C (sv) 1994-02-10
LTIP1683A (en) 1995-07-25
JP2740993B2 (ja) 1998-04-15
KR870009717A (ko) 1987-11-30
LV10357B (en) 1996-04-20
SI8710681A8 (en) 1996-10-31
SG154294G (en) 1995-03-17
DK169988B1 (da) 1995-04-24
GB2189698A (en) 1987-11-04
US4786505A (en) 1988-11-22
NO174239B (no) 1993-12-27
NZ220096A (en) 1990-04-26
PH25701A (en) 1991-09-18
GR890300058T1 (en) 1989-06-22
GB8610572D0 (en) 1986-06-04
EP0247983A3 (en) 1988-10-19
ES2135443T3 (es) 1999-11-01
EP0247983B1 (en) 1993-01-07
DK215887D0 (da) 1987-04-28
AU601974B2 (en) 1990-09-27
IL82911A (en) 1991-06-30
YU46192B (sh) 1993-05-28
LT3699B (en) 1996-02-26
ZA872378B (en) 1987-12-30
EP0567201B1 (en) 1999-09-15
DE3751860D1 (de) 1996-08-22
AU7191287A (en) 1987-11-05
PL265416A1 (en) 1988-07-21
PT84785B (pt) 1989-12-29
PL151631B1 (en) 1990-09-28
ATE140387T1 (de) 1996-08-15
FI871913L (fi) 1987-10-31
GR3007434T3 (el) 1993-07-30
LV10357A (lv) 1995-02-20
ATE184482T1 (de) 1999-10-15
IE871107L (en) 1987-10-30
HK52897A (en) 1997-05-02
GR3020734T3 (en) 1996-11-30
JPH05294831A (ja) 1993-11-09
CA1292693C (en) 1991-12-03
CN87103284A (zh) 1987-11-11
JPS62258320A (ja) 1987-11-10
DE247983T1 (de) 1990-09-27
HRP920854B1 (en) 1998-12-31
JP5069807B2 (el) 1993-10-01
FI871913A0 (fi) 1987-04-29
IS3221A7 (is) 1987-10-31
PT84785A (en) 1987-05-01
EP0247983A2 (en) 1987-12-02
NO871790L (no) 1987-11-02
EP0567201A3 (en) 1995-06-07
HRP920854A2 (en) 1994-10-31
DZ1077A1 (fr) 2004-09-13
AR240250A1 (es) 1990-03-30
DD273197A5 (de) 1989-11-08
ES2006457A4 (es) 1989-05-01
RU2095054C1 (ru) 1997-11-10
EP0496437A2 (en) 1992-07-29
DK215887A (da) 1987-10-31
NO871790D0 (no) 1987-04-29
LV5760A4 (lv) 1996-12-20
IS1917B (is) 2004-03-15
NO174239C (no) 1994-04-06
ES2091971T3 (es) 1996-11-16
CN1020852C (zh) 1993-05-26
LV5760B4 (lv) 1997-06-20
ES2006457T3 (es) 1994-01-01
EP0496437A3 (en) 1992-09-02
HUT43954A (en) 1988-01-28
CY1810A (en) 1995-10-20
KR910004579B1 (ko) 1991-07-06
FI90393B (fi) 1993-10-29
HK135294A (en) 1994-12-09
EP0496437B1 (en) 1996-07-17

Similar Documents

Publication Publication Date Title
GR3032101T3 (en) Vehicles for oral administration of a specific pharmaceutically active acid labile substance.
NO178564C (no) Framgangsmåte for framstilling av et system for administrering av aktive medikamenter gjennom slimhinner
AU588202B2 (en) Dosage form for delivering acid sensitive beneficial agent
EG18517A (en) Pharmaceutical formulations of acid labile substances for oral use
FI890508L (fi) Menetelmä farmaseuttisesti aktiivisten 3-indolipalorypälehappojohdannaisten valmistamiseksi
NO883667D0 (no) Kapsel for farmasoeytisk virksomme innholdsstoffer av en droge.
FI875645L (fi) Menetelmä nestemäisen annostelumuodon valmistamiseksi farmaseuttisesti aktiivisen aineen oraalista antoa varten
FI885460L (fi) Menetelmä suun kautta annettavaksi tarkoitetun, aktiiviyhdistettä kontrolloidusti vapauttavan farmaseuttisen formulaation valmistamiseksi
NO863061D0 (no) Fremgangsmaate for fremstilling av fysiologisk aktive fenoksyeddiksyrederivater.
IL83349A (en) Stable pharmaceutical composition comprising cimetidine polymorph b suitable for oral administration
GB2206493B (en) Inophoresis device for the percutaneous or perungual administration of a dissolved or partially dissolved substance
PT86000A (en) Pharmaceutically active compounds
AU2228888A (en) Aqueous pharmaceutical preparation for oral administration
FI871087A7 (fi) Menetelmä terapeuttisesti aktiivisten 1,2,3,4-tetrahydro-3-karbamoyyli-2-tiokso/okso-5-pyrimidiinikarboksyylihappojohdannaisten valmistamiseksi
NO883500L (no) Fremgangsmaate for fremstilling av et farmasoeytisk aktivt nitrometan.
AR245125A1 (es) Procedimiento para la preparacion de compuestos arilpiperazinil-alquilenfenil-p-heterociclicos y sus sales de adicion de acidos farmaceuticamente aceptables.
AU2617288A (en) Pharmaceutical formulations for transdermal administration
HUT41757A (en) Process for producing pharmaceutical compositions containing e-desmethyl-mevalonic acid derivatives and process for producing the active agents
AR244243A1 (es) Procedimiento para preparar timolinfotropina.
FI854985A7 (fi) Menetelmä farmaseuttisesti aktiivisten N-substituoitujen atsiridiini-2-karboksyylihappojohdannaisten valmistamiseksi.
GR3032639T3 (en) Vehicles for oral adminstration of pharmaceutically active acide labile substances.
GB8721749D0 (en) Administration of pharmacologically active substances
IL81926A0 (en) Pharmaceutical compositions for the oral administration of active proteins
HRP920855B1 (en) Pharmaceutical formulations of acid labile substances for oral use
ZA878046B (en) Pharmaceutically active compounds